ArticleAnnals of medicine2026
The clinical significance of exploring concurrent nephropathy in patients with primary renal malignancies.
Article in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to compare the clinicopathological features and clinical outcomes between patients with primary renal malignancies with pathologically diagnosed nephropathy (PRMN) and those with isolated primary renal malignancies (IPRMs).
methodsWe enrolled 31 patients with PRMN and 31 matched controls with IPRM between 2013 and 2023. Clinical characteristics, tumour pathological features, therapeutic interventions and prognostic outcomes were systematically analysed. Nephropathy was diagnosed by immunofluorescence, immunohistochemistry and light microscopy.
resultsPatients in the PRMN group were younger, with a higher proportion of males and those with a smoking history. Preoperative and postoperative serum creatinine (Scr) were significantly higher in the PRMN group than in the IPRM group, while estimated glomerular filtration rate (eGFR) was significantly lower. Peritumoural renal tissues in the PRMN group showed more severe pathological changes, including global glomerulosclerosis (GS), segmental glomerulosclerosis (SS), and interstitial fibrosis and tubular atrophy (IFTA). Tumour treatment modalities did not differ significantly between groups. However, the PRMN group had a significantly higher all-cause mortality rate (19.4% vs. 0%,
conclusionsPatients with PRMN exhibited distinct clinicopathological characteristics, factors associated with disease progression, and a higher incidence of adverse outcomes compared to those with IPRM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.